Ashwin Unnikrishnan

@ashwinkrish

Researcher & Lab Head Sydney. Working on & . Interested in . Tweets/opinion are my own.

Vrijeme pridruživanja: prosinac 2008.

Tweetovi

Blokirali ste korisnika/cu @ashwinkrish

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ashwinkrish

  1. Prikvačeni tweet

    My team is expanding! We are looking for someone interested in working on , using , molecular biology and cell biology techniques to join us as an R.A., so please help us spread the word!

    Poništi
  2. Feb 4 is 2020. Let's all work together to tackle this scourge that we have yet to fully overcome. Perseverance and commitment can only succeed with sufficient funding, so please continue supporting research

    Poništi
  3. proslijedio/la je Tweet
    29. sij

    The McCulloch & Till Award Winner is Mark Dawson! is a clinician-scientist group leader at the Peter MacCallum Cancer Centre in Australia. studies epigenetic regulation in normal and malignant haematopoiesis. Learn more:

    Poništi
  4. proslijedio/la je Tweet
    28. sij

    Congratulations to Harvey Lodish , (Mark Dawson) and Jennifer , the 2020 recipients of the Donald Metcalf, Till and McCulloch and Janet Rowley awards, respectively, of . Looking fwd to your presentations!

    Poništi
  5. proslijedio/la je Tweet
    22. sij

    One of the hardest things to figure out as a PI, especially a young PI, is "when to hold em and when to fold em" with respect to appealing/revising a paper with tough reviews. A few thoughts

    Prikaži ovu nit
    Poništi
  6. 14. sij

    I wanted to highlight this very important thread. I urge everyone to have a read

    Poništi
  7. 13. sij

    Thoughts and constructive comments welcome. Please feel free to message or email me

    Prikaži ovu nit
    Poništi
  8. 13. sij

    Happy to present pre-print of our latest findings on in . This is the first from my independent lab and was led by my grad student Govardhan, plus wonderful collaborators:

    Prikaži ovu nit
    Poništi
  9. proslijedio/la je Tweet
    10. pro 2019.

    Impressive dataset of 1300 AML&MDS genomes & transcriptomes by & . A bit surprising: only 5 genes mutated per pat - median for targeted NGS is 3-4 already. Noncoding regions not analyzed yet-a lot of exciting insights probably still hidden there!

    Poništi
  10. proslijedio/la je Tweet
    10. pro 2019.

    Last but not least- we had to wait for the final day of for positive Ph3 data in AML. CC-486 (oral azacitidine) maintenance improves OS (but doesn’t increase cure rate) of older AML pts in CR. Interesting option for pts who got induction but then can’t proceed to alloSCT

    Poništi
  11. 10. pro 2019.
    Poništi
  12. 4. pro 2019.

    For those packing for ....so put away that winter jacket,

    Poništi
  13. 3. pro 2019.

    This group photo has come out well! Kudos to those who put up the environmentally conscious decorations (big props to Nicole and Bonnie). Welcome, to the newcomers, and looking forward to a new year (and a new decade!)

    Poništi
  14. proslijedio/la je Tweet
    Poništi
  15. proslijedio/la je Tweet
    1. pro 2019.

    Fascinating pre-print in on hematopoiesis in long-lived naked-mole rats: More quiescent HSCs than in mice and no sign of some key hematopoietic TFs like RUNX1, GFI1B, GFI1, etc.

    Poništi
  16. proslijedio/la je Tweet
    25. stu 2019.

    Excited to share our study on genomic analysis of histiocytosis neoplasms in . >250 patients from and reference centers in France, Belgium, Spain, (plus histiocytosis patients worldwide via MSK's Make-An-IMPACT):

    Prikaži ovu nit
    Poništi
  17. 22. stu 2019.
    Poništi
  18. proslijedio/la je Tweet
    22. stu 2019.

    Our study is out ! Want to identify proteins interacting with your favorite RNA (even if its low abundance) or its specific regions? Try incPRINT, our new RNA-centric technology that does not rely on RNA pull-downs and mass spectrometry.

    Poništi
  19. proslijedio/la je Tweet
    22. stu 2019.

    What AML subtypes should be prioritized in BET bromodomain inhibitors trials to impair LSCs? Check our latest report out now in Leukemia Research!

    Poništi
  20. proslijedio/la je Tweet
    21. stu 2019.

    Such an exciting time: work we began over a decade ago to understand the fundamental biology of hemoglobin switching, which highlighted BCL11A, has now led to multiple promising therapeutic avenues for and !

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·